Table 2.
Ligand | Docking Poses |
|||||||
---|---|---|---|---|---|---|---|---|
Dock-1 |
Dock-2 |
Dock-3 |
Dock-4 |
|||||
Binding | RMSD | Binding | RMSD | Binding | RMSD | Binding | RMSD | |
a | −9.2 | 1.67 | −9.2 | 1.83 | −9.2 | 1.04 | −9.1 | 1.13 |
Lig-783 | −7.9 | 0.97 | −7.9 | 0.82 | −7.9 | 0.97 | −7.6 | 0.85 |
Lig-1022 | −7.1 | 0.32 | −7.1 | 0.61 | −7.0 | 1.00 | −6.9 | 0.93 |
Lig-1392 | −7.2 | 0.36 | −7.1 | 0.28 | −7.0 | 0.82 | −7.0 | 0.77 |
Lig-2177 | −8.5 | 2.43 | −8.5 | 2.26 | −8.3 | 1.39 | −8.0 | 1.41 |
Lig-3444 | −8.4 | 3.22 | −8.3 | 4.51 | −8.3 | 4.64 | −8.1 | 5.09 |
Lig-6199 | −7.0 | 3.16 | −7.0 | 3.17 | −6.8 | 3.05 | −6.5 | 3.09 |
The N-[(S)-([(benzyloxy) carbonyl]amino methyl)(hydroxy) phosphoryl]-L-leucyl-4-methyl-L-leucine (5H9) was re-docked with the same docking procedure of the ligand studied.